Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut

Merck’s PD-(L)1 blockbuster Keytruda has held a steady march into earlier lines of therapy, with cervical cancer next up on its checklist. After flashing winning data as part of a chemo combo last month, Keytruda now has the FDA’s green light in first-line patients.